Nolan McLean Vertigo Sidelines Mets Rookie From Team USA Workout — Medical, Roster and WBC Implications

Table of Contents

1. Key Highlights
2. Introduction
3. What unfolded: timeline and immediate implications
4. Understanding vertigo: causes, diagnosis and treatment relevant to pitchers
5. Why the World Baseball Classic amplifies medical decisions
6. Team USA’s pitching depth and potential contingency plans
7. The Mets’ calculus: rookie workload, service time, and organizational interests
8. How medical teams clear pitchers after vestibular episodes
9. Performance risks specific to pitchers with vestibular symptoms
10. Historical parallels: when sudden medical issues reshaped teams
11. How managers balance competitive priorities and player long-term health
12. What to watch next: indicators that will determine McLean’s WBC status
13. The broader implications for player care in international play
14. Real-world examples of quick recoveries and prolonged rehabilitation
15. Media and fan reactions: managing expectations
16. How McLean’s trajectory could shape his career
17. Practical takeaways for teams managing short-term medical issues
18. The competitive calculus for Team USA in pool play and beyond
19. Legal and insurance considerations in international play
20. What the media narrative should avoid
21. Final operational scenarios and likely outcomes
22. FAQ

Key Highlights

• Nolan McLean missed Team USA's first workouts after experiencing vertigo-like symptoms; symptoms had reportedly cleared by Tuesday but his participation in early exhibitions is delayed.
• Team USA and the New York Mets are monitoring McLean; contingency plans include using a patchwork group for an exhibition start and potential replacements like Clay Holmes, Clayton Kershaw or Ryan Yarbrough if McLean cannot make his scheduled March 10 start against Italy.
• Vertigo-related issues carry specific diagnostic and treatment pathways that can yield rapid recovery, but they require careful pitcher-specific management because balance and spatial orientation are critical to performance and safety.

Introduction

Nolan McLean arrived on the Major League stage last season with a small body of work but significant attention. The New York Mets have already leaned on the right-hander in limited innings, and Team USA planned to bring him into the World Baseball Classic rotation for a pool-play start against Italy on March 10 in Houston. That plan stalled when McLean reported vertigo-like symptoms following a Friday night outing and remained in Port St. Lucie rather than joining the U.S. contingent in Arizona for the opening workouts.

Reports from MLB.com’s Mark Feinsand and coverage from the New York Post’s Joel Sherman confirm the symptoms had abated by Tuesday, but the brief episode created uncertainty around exhibitions and the WBC start schedule. The situation highlights two overlapping realities: the fragility of medical windows for pitchers and the unique constraints of international tournaments. The conversation touches on medical diagnostics, roster flexibility, and competitive strategy—each consequential for a young pitcher with only eight Major League appearances to his name.

This article unpacks the timeline of McLean’s absence, examines what vertigo means for elite athletes—especially pitchers—reviews Team USA’s relief and replacement options, and outlines the decisions the Mets and Team USA will face in the coming days. It also places this episode in a broader context of athlete health management during condensed international competitions.

What unfolded: timeline and immediate implications

The sequence began with McLean experiencing vertigo-like symptoms on a Friday night, according to reporting by Mark Feinsand. As a precaution, McLean remained in Port St. Lucie rather than traveling to Arizona with the U.S. team. Team USA had planned to use the Mets rookie in an early exhibition start—one intended as a ramp-up ahead of the March 10 pool-game assignment against Italy—so his absence triggered immediate adjustments.

By Tuesday, team officials said McLean’s symptoms had cleared. Joel Sherman reported that if McLean were able to make a scheduled start for the Mets on Wednesday, the door would remain open for him to travel and make the March 10 WBC start. That scenario depends on efficient medical evaluation, a clean bill of health from team physicians, and the Mets’ willingness to clear innings for a rookie with a limited big-league track record.

In the interim, Team USA opted to use a “patchwork group” of pitchers for the exhibition that McLean was supposed to start. Organizational contingency planning already had alternatives: the roster includes experienced arms such as Clay Holmes, Clayton Kershaw, and Ryan Yarbrough. Additionally, the U.S. designated pitcher pool was bolstered by the addition of Joe Ryan from the Minnesota Twins, increasing in-tournament options should McLean remain unavailable.

The immediate practical implications are straightforward. A single vertigo episode can be transient and quickly resolved, or it can mark the onset of a vestibular problem that requires weeks of treatment and rehabilitation. For a pitcher, any impairment to balance, head movement tolerance, or visual stability undermines the ability to throw with control and to field. That raises two questions teams must answer almost concurrently: can McLean clear medical and performance tests quickly enough for a March 10 start, and how does the team preserve both his long-term health and its competitive objectives in a single-elimination tournament setting?

Understanding vertigo: causes, diagnosis and treatment relevant to pitchers

Vertigo refers to a perception of spinning or motion when none exists. It is a symptom—not a diagnosis—and it arises from several potential causes. Clinicians group vestibular complaints into peripheral causes, which originate in the inner ear, and central causes, which arise within the brainstem or cerebellum. Common peripheral causes include benign paroxysmal positional vertigo (BPPV), vestibular neuritis, and Ménière’s disease. Central causes encompass conditions such as stroke or demyelinating disease; though rarer in young athletes, they are critical to rule out.

For athletes, and pitchers in particular, the chief concerns are twofold: immediate safety and the integrity of performance. A pitcher experiencing dizziness or imbalance is at high risk for injury during high-velocity, high-precision movements. The delivery itself requires coordinated head and body mechanics and precise visual focus on the target. A disrupted vestibular system undermines those functions and elevates the chance of errant throws, slips on the rubber, or falls while fielding.

Diagnosis typically begins with a careful history: timing, triggers, associated symptoms (hearing loss, ear fullness, tinnitus, headache, double vision, weakness), and prior episodes. Physical examination then often includes positional testing; the Dix-Hallpike maneuver is a standard bedside test for BPPV. Observing nystagmus—abnormal eye movements—during positional changes can point toward a peripheral vestibular cause. Where central causes are suspected, or if the clinical picture is atypical, magnetic resonance imaging (MRI) is the definitive next step to evaluate for structural brain conditions.

Treatment varies with the diagnosis. BPPV frequently responds to canalith repositioning maneuvers, the most familiar being the Epley maneuver, which moves loose calcium crystals out of the semicircular canal where they provoke positional vertigo. Vestibular neuritis, an inflammation of the vestibular nerve, may require a combination of vestibular suppressant medications in the acute phase and vestibular rehabilitation therapy over weeks to months. Ménière’s disease involves episodic vertigo associated with fluctuating hearing loss and may be managed with dietary changes, diuretics, and other targeted measures.

Pitchers generally receive expedited evaluation. Teams employ sports medicine physicians and vestibular specialists for rapid assessment because the margin between allowing a player to compete and safeguarding health is narrow. The goal is to determine whether symptoms are self-limited and safe to monitor, or whether they signal a more serious condition requiring rest and targeted therapy.

Why the World Baseball Classic amplifies medical decisions

International tournaments like the World Baseball Classic compress high-stakes competition into a short timeframe. Managers and medical staffs must reconcile player availability with travel schedules, quarantine protocols (when applicable), and the intensity of single-elimination phases. That compression influences both the medical evaluation timeline and strategic roster decisions.

The WBC’s schedule reduces the cushion teams have to wait for a player’s recovery. An ailment that might justify a three- or four-week recovery in the regular season can become a tournament-defining absence when games occur every few days. Conversely, a transient episode that ordinarily would be observed for safety reasons can be cleared more quickly when imaging and specialist input is readily available, and the player’s symptoms resolve without residual deficits.

Tournament rules around pitcher usage and replacement matter. The WBC has employed designated pitcher pools and substitution mechanisms to allow teams to adapt to injuries and logistics. The source reporting details that Joe Ryan was added to Team USA’s designated pitcher pool, providing an extra option for knockout-round starts. The existence of a pitcher pool enables managers to shift roles—shortening, lengthening or reassigning starts—without entirely compromising internal rotation plans.

Physicians must balance two conflicting imperatives. First, they must ensure player safety and avoid returning someone to competition while symptomatic, since a recurrence during a high-stress moment could risk performance collapse or a secondary injury. Second, they must provide clear, evidence-based timelines that allow coaches to manage the roster. For McLean, the window between his mid-week exhibition start (which he missed) and March 10 represented both a medical evaluation window and a strategic hinge point for Team USA’s rotation.

Team USA’s pitching depth and potential contingency plans

Team USA assembled a roster with considerable top-end talent and veteran depth: frontline options like Tarik Skubal were planned for limited assignments, while legendary pitchers such as Clayton Kershaw bring experience and temperament for big moments. Lefty Ryan Yarbrough offers a soft-tossing change of pace, and the bullpen includes late-inning specialists like Clay Holmes. The addition of Minnesota Twins ace Joe Ryan to the designated pitcher pool broadened available choices for the knockout rounds.

Contingency planning typically unfolds along several avenues:

• Short-term patchwork for exhibitions: When a projected starter cannot make an exhibition, managers fill innings with minor starters, bullpen arms, or a rotation of relievers. This choice minimizes the impact on the competitive pool schedule while preserving primary arms for the official games.
• Reassigning starts within the active roster: If McLean cannot make the March 10 start but is still in the tournament, managers could shift another rostered starter into that slot or insert an experienced pitcher for the pool finish. Clayton Kershaw and Ryan Yarbrough are explicitly mentioned as viable in-situ options.
• Utilizing the pitcher pool: The WBC rules allow teams to call upon pitchers in the designated pool for semifinal or final assignments or to replace injured pitchers. Joe Ryan’s addition increases flexibility for the knockout phase.
• Insertion of bullpen-by-committee: Some managers choose to span innings across several relievers to protect a depleted rotation or to counter a matchup. This streaming approach trades a traditional starter’s length for matchup variety and bullpen depth.

The immediate choice for Team USA hinges on the medical assessment of McLean and whether the Mets will clear him for a scheduled pre-WBC outing. If McLean shows normal balance, resolves symptoms completely, and demonstrates live arm readiness in a Mets appearance, the team could keep him on track for the March 10 game. If not, the U.S. will rely on veteran depth and the pitcher pool to keep competitive options open.

The Mets’ calculus: rookie workload, service time, and organizational interests

From the Mets’ perspective, McLean’s health has multiple dimensions. First, the organization must preserve a young pitcher’s long-term development trajectory. McLean has only appeared eight times in the majors, per the source. That limited exposure creates incentives to manage him conservatively. Second, the Mets must weigh short-term competitive aims against player safety; allowing him to throw meaningful innings for Team USA could accelerate experience, but it may risk injury or fatigue before the MLB season.

Clubs generally require their players to report readiness and satisfy medical checks before granting permission for international competition. When a player experiences a medical episode during spring training or just before a tournament, the parent club’s medical staff often take a lead role in clearing him. For a rookie with a small MLB sample, the Mets’ physicians will likely prioritize vestibular stability and reproducible performance metrics such as pitch velocity, command, and ability to navigate full mound mechanics without dizziness or lightheadedness.

Another consideration is innings and workload monitoring. Even when medically cleared, teams often limit innings in spring exhibitions and international starts to avoid sudden spikes in workload. If McLean were cleared to join Team USA but only able to provide short stints, the Mets and Team USA would have to agree on usage that protects his arm while keeping the team competitive.

Finally, there is an optics and contractual element. Clubs maintain leverage in discussions about player participation in external competitions. They can deny or impose conditions on participation based on health or developmental concerns. If the Mets prefer a cautious approach for McLean, they have tools to advocate reduced usage or to require medical re-evaluation before travel.

How medical teams clear pitchers after vestibular episodes

When a pitcher reports vertigo or balance problems, a staged approach to clearance is common:

1. Immediate assessment and stabilization: Teams assess symptom severity and check for red flags—neurologic deficits, double vision, new headaches, focal weakness. If red flags exist, urgent imaging and specialist referral follow.
2. Focused vestibular testing: For peripheral vestibular causes, clinicians perform bedside positional tests like Dix-Hallpike to look for classic findings. Observation for nystagmus and symptom provocation guides diagnosis.
3. Imaging where appropriate: MRI is typically reserved for suspected central causes or atypical presentations. In the absence of concerning neurologic signs, imaging may not be necessary.
4. Symptom resolution and functional testing: Clearance requires not only absence of subjective vertigo but the ability to tolerate head movement and to perform sport-specific tasks. For pitchers, this means throwing off flat ground, pads, and then a bullpen session on the mound while being observed for dizziness, visual disturbance, or disequilibrium.
5. Gradual ramping of workload: If the bullpen session is symptom-free, the pitcher progresses to live batting practice and then to short-inning, monitored game action. Each step evaluates the stability of the vestibular system under increasing stress.
6. Return-to-play decision: Team physicians and trainers make a joint decision with the club and national team, weighing the player’s report, objective findings, and the competitive calendar.

These steps prioritize safety while aiming to minimize unnecessary absences. A cause like BPPV often resolves rapidly with repositioning maneuvers, meaning a pitcher might return within days. A vestibular neuritis case could take weeks. Therefore, the specifics of the diagnosis are crucial for the timeline.

Performance risks specific to pitchers with vestibular symptoms

Pitching involves repeated, rapid rotations of the head and torso; fine visual tracking; and split-second balance adjustments. Vestibular symptoms jeopardize:

• Control: Dizziness can disrupt spatial judgment, affecting the ability to land consistently on the rubber and to locate pitches.
• Fielding: A pitcher must react quickly to batted balls or comebackers; compromised balance increases injury risk.
• Injury cascade: A fall or awkward movement resulting from vertigo can produce musculoskeletal injuries unrelated to the vestibular system.
• Confidence and mechanics: Athletes returning from vestibular problems often compensate by altering mechanics subconsciously. That can change stress patterns on the arm, potentially increasing elbow or shoulder risk.

Consequently, coaching staffs and medical personnel often enforce conservative progressions. Even if symptoms resolve, teams monitor for lingering deficits that could reappear under fatigue or stress. The WBC’s compressed timeline complicates management because there is less opportunity for graded exposure than in the regular season.

Historical parallels: when sudden medical issues reshaped teams

International and domestic tournaments have featured sudden medical episodes that forced roster adjustments. While each instance is unique, the pattern is familiar: an urgent medical concern creates both immediate tactical gaps and longer-term questions about a player’s health.

One illustrative type of case involves concussions and post-concussive vestibular symptoms. Players who sustain head impacts sometimes experience dizziness, balance problems, and light sensitivity—conditions requiring strict rest, graded exertion and vestibular rehab. Teams have typically erred on the side of caution, sitting players until complete symptom resolution and safe exertional testing.

Another common example is sudden inner-ear issues—BPPV flares that incapacitate a player for brief periods. Because these problems can respond quickly to repositioning maneuvers, management often allows quick returns once testing is completed. The critical task is distinguishing these transient peripheral causes from central neurologic concerns that require extensive evaluation.

The key lesson from past episodes is that roster flexibility and clear medical protocols reduce disruption. Teams that lean on depth and maintain clear communication between national and club medical staffs navigate these crises most effectively.

How managers balance competitive priorities and player long-term health

Coaches face tradeoffs when a player could be available in a few days. A manager who prioritizes winning the tournament might press for a faster return. Conversely, a manager representing a club may insist on a more cautious plan to preserve a player for the regular season. In McLean’s case, that tension involves the Mets and Team USA medical and coaching staffs.

Best practice blends three elements:

• Objective medical criteria: Return-to-play protocols grounded in reproducible tests reduce subjective pressure on decision-makers.
• Transparent communication: Players, club physicians and tournament staff must share data and perspectives; hidden agendas or siloed information exacerbate mistrust.
• Contingency planning: Because medical recovery is uncertain, pre-established replacement plans allow teams to make decisions without scrambling.

Team USA’s reliance on experienced arms like Kershaw and Yarbrough, plus the pitcher pool additions, reflects an appreciation of these dynamics. It preserves the roster’s competitiveness while leaving room for McLean to return if cleared.

What to watch next: indicators that will determine McLean’s WBC status

The immediate timeline hinges on several signals:

• Medical clearance from Mets’ team physicians: Clearance for a Wednesday Mets start would be the clearest sign McLean is moving toward the WBC roster.
• Bullpen and live batting practice results: A symptom-free bullpen on the mound carries more weight than subjective reports of feeling better.
• Availability of a Mets start prior to March 10: If McLean can throw a scheduled Mets outing and show stability through fatigue, his WBC start becomes more feasible.
• Reports from Team USA medical staff: Confirmation that team physicians accept the Mets’ clearance or have independently evaluated McLean will reduce uncertainty.
• Adjustments to the exhibition plan: Team USA’s decision to use a patchwork rotation suggests the organization is preserving the March 10 slot as a hinge; the manner and duration of that patchwork usage will hint at their expectations for McLean’s readiness.

Fans and media should watch both the hard data—velocity, pitch counts, observed mechanics—and soft signals such as how pitchers describe their confidence and balance in the lead-up to the game.

The broader implications for player care in international play

McLean’s episode underscores why coordinated international player care matters. Modern sports medicine has advanced protocols for quick, evidence-based evaluations of vestibular complaints. For tournaments that pull players from disparate clubs, standardized assessment approaches would minimize disagreement and expedite safe clearances.

Tournament organizers benefit when national teams and clubs agree on shared standards and when player welfare takes precedence over short-term gains. The WBC can serve as an opportunity to codify best practices—streamlined lines of communication, agreed medical checkpoints, and accessible scans or specialist evaluations within host cities.

From an organizational standpoint, clubs should maintain transparent policies around player participation in international events. Clear expectations reduce last-minute friction. For players, the most practical approach is to report symptoms early; delaying disclosure often compounds risk and leads to rushed decisions that can prolong absence.

Real-world examples of quick recoveries and prolonged rehabilitation

Vestibular conditions run a spectrum. A pitcher who experiences a single BPPV episode can undergo an Epley maneuver and resume normal activity within days, provided positional provocation testing is negative and functional tasks are tolerated. On the other end, vestibular neuritis can leave athletes symptomatic for weeks, requiring vestibular rehabilitation that addresses gaze stabilization, habituation exercises and balance retraining.

Teams have managed both types of scenarios. When a player’s complaint is positional and clearly peripheral, a quick resolution and return to play are common. When symptoms are variable, or when there’s associated head trauma or neurologic signs, teams mandate conservative timelines. For athletes under national team consideration, the difference between a rapid recovery and a protracted course distinguishes whether a player participates.

The practical message for McLean’s case is that the absence of red flags and the rapid resolution of symptoms are encouraging. Still, the final determination rests on functional verification: can he pitch without dizziness, and can he tolerate the head motions and fatigue accompanying competitive innings?

Media and fan reactions: managing expectations

High-profile international competitions generate intense attention. A rookie’s sudden absence becomes news, speculation fills the void, and multiple stakeholders—fans, pundits, teammates—voice opinions. Teams must manage messaging carefully, providing accurate medical updates while protecting players’ privacy.

Clear, timely statements that report both the diagnosis and the current functional state reduce rumor and allow supporters to set realistic expectations. Team USA and the Mets have offered measured updates: McLean experienced vertigo-like symptoms, stayed home for evaluation, and had symptoms abated by Tuesday. That level of transparency helps quell unfounded speculation about more serious conditions.

From a competitive psychology standpoint, the team’s handling of the situation signals to other players that health is prioritized. That culture affects recruitment for future international tournaments; players more readily commit to play when they trust that clubs and national teams will act responsibly.

How McLean’s trajectory could shape his career

For a pitcher early in his career, episodes like this can be minor blips or inflection points depending on outcomes. A brief, resolved vestibular event that permits McLean to participate in the WBC could provide valuable big-game experience and a boost in confidence. Conversely, a protracted problem would interrupt his development timeline and necessitate careful rebuilding.

Beyond the immediate health considerations, participating in a high-profile event like the WBC has career ramifications: scouts, front offices, and the broader baseball public gauge how players perform under pressure. For a promising rookie, positive exposure can accelerate trust from managers and the front office. The Mets therefore weigh both health and upside in their permission for McLean to pitch on an international stage.

The broader organizational lesson is the value of graduated exposure. Young pitchers often benefit more from controlled, monitored appearances that build experience without overwhelming workload capacity. If McLean’s medical evaluation indicates any residual vulnerability, the safer choice prioritizes measured innings and a planned ramp to the MLB season.

Practical takeaways for teams managing short-term medical issues

Teams that manage short-term medical episodes effectively tend to share several traits:

• Proactive communication: Early disclosure by the player and immediate evaluation reduce time lost and uncertainty.
• Clear medical leadership: A designated physician or medical lead who coordinates club and national evaluations streamlines decisions.
• Depth planning: Building rosters with redundant skills—lefties, soft-tossers, late-inning specialists—mitigates the shock of losing a projected starter.
• Conservative ramp-ups: Prioritizing controlled exposures and objective functional testing prevents premature returns and secondary injuries.
• Education and trust: Educating players about vestibular symptoms and the rationale for conservative approaches builds compliance and reduces pressure to return prematurely.

McLean’s situation illustrates why these practices matter. His symptoms resolved quickly, but the intervening days required collaboration and prudence from both the Mets and Team USA.

The competitive calculus for Team USA in pool play and beyond

Team USA’s pool-play objective remains advancement to the knockout rounds, where the tournament’s compressed intensity accelerates the value of reliable starters and shutdown relievers. The March 10 game against Italy could determine seeding or progression; therefore, managers must weigh whether to lean on veterans or to preserve arms for later rounds.

Using an available veteran or the pitcher pool to replace a single start preserves flexibility. If McLean returns in time, he can provide length in a middle-pool opportunity. If he does not, the presence of Kershaw, Yarbrough, and bullpen pieces like Holmes allows the U.S. to pivot without a catastrophic drop-off in capability.

The data-driven approach recognizes that tournament momentum depends on both rotation reliability and bullpen depth. Managers often prefer to keep innings high-value and not waste top arms in low-leverage exhibitions. That calculus explains Team USA’s willingness to use a patchwork group for the exhibition while preserving better arms for officially scheduled pool and knockout games.

Legal and insurance considerations in international play

An often-overlooked facet of international competitions is the legal and insurance framework surrounding player injuries. Clubs and national organizations typically have agreements covering medical costs and liabilities when players participate overseas. Those agreements also govern disputes over fitness for play and determine which medical staff has final authority.

For players whose initial symptoms occur in club contexts—like McLean in Port St. Lucie—the club’s medical team commonly takes the lead on evaluation. The national team’s physicians then confirm findings. In rare disputes, insurance provisions and tournament rules can arbitrate competing interests.

Awareness of these frameworks helps explain why clubs may insist on additional testing or deny clearance until a full evaluation is completed. Those measures protect the player and the organization from long-term harm and financial exposure.

What the media narrative should avoid

Speculation about the severity or permanence of medical conditions harms players and fans alike. Responsible coverage focuses on facts and avoids prognostic overreach. In McLean’s case, verified reporting has already clarified the timeline and noted symptom resolution. Further reporting should center on official medical findings and measured progress updates rather than presuming a worst-case scenario.

Similarly, coverage that frames every medical absence as an organizational ploy undermines trust. Clubs and national teams generally prefer to keep players healthy; painting them as obstructionist when they insist on standard medical evaluation distorts incentives.

Journalistic responsibility includes explaining the medical pathways and the reasons for conservative approaches. That context helps readers appreciate why teams hesitate to clear players immediately—and why such caution ultimately protects careers.

Final operational scenarios and likely outcomes

Several realistic outcomes exist for McLean over the next week:

• Full clearance and Mets start before March 10: If McLean completes a symptom-free bullpen and makes a scheduled start for the Mets without recurrence, Team USA will likely retain him for the March 10 pool game.
• Partial clearance with limited innings: Medical staff might clear McLean to participate in the WBC but restrict his innings, using him for single short stints rather than a full start.
• Continued monitoring and delayed participation: If symptoms recur or testing yields uncertainty, Team USA will hold McLean out of the March 10 start and call on an in-roster veteran or a pitcher from the designated pool.
• Conservative approach leading to withdrawal: In the unlikely event that symptoms persist or a more serious diagnosis emerges, the Mets and Team USA could agree to withdraw McLean from the tournament and preserve his long-term health.

Each scenario has tactical and developmental implications. The party most directly affected is McLean himself; how he and his medical team respond in the next 48–72 hours will define the path forward.

FAQ

Q: What exactly did Nolan McLean experience, and how severe is it? A: Reports indicate McLean experienced vertigo-like symptoms following a Friday night event and stayed in Port St. Lucie for evaluation. Sources say his symptoms had cleared by Tuesday. “Vertigo-like symptoms” describe a subjective sense of spinning or imbalance and require medical assessment to determine the cause and severity.

Q: Will McLean miss his March 10 World Baseball Classic start against Italy? A: That depends on his medical clearance and demonstrated ability to pitch without dizziness. If he can make a scheduled Mets start and remain symptom-free through bullpen and live-action testing, he could still start on March 10. Team USA has prepared contingency plans that include veteran replacements and pitcher-pool additions.

Q: What are common causes of vertigo in athletes? A: Common causes include benign paroxysmal positional vertigo (BPPV), vestibular neuritis, Ménière’s disease, and, less commonly in young, otherwise healthy athletes, central causes that warrant imaging. Accurate diagnosis requires clinical testing and sometimes imaging.

Q: How quickly do athletes usually recover from vertigo? A: Recovery timelines vary. BPPV often responds quickly to repositioning maneuvers and can resolve in days, while vestibular neuritis can take several weeks of rehabilitation. The specific diagnosis determines the timeline.

Q: What tests determine if a pitcher is safe to return? A: Clinicians use positional tests like the Dix-Hallpike to identify BPPV, observe for nystagmus, and perform neurologic exams to rule out central causes. Functional testing includes bullpen sessions, live batting practice, simulated game situations, and monitoring for dizziness during increasing exertional loads.

Q: Who makes the final call on McLean’s participation—the Mets or Team USA? A: Both parties collaborate. The Mets’ medical team typically leads the initial evaluation when symptoms arose in a club setting, and Team USA’s physicians will review findings and either accept the clearance or request additional testing. The final decision is commonly a joint one that prioritizes player health.

Q: If McLean cannot pitch, who replaces him for Team USA? A: Team USA has veteran options such as Clayton Kershaw and Ryan Yarbrough, and bullpen help like Clay Holmes. The U.S. also added Joe Ryan to the designated pitcher pool, providing further options for knockout-round assignments.

Q: Could this affect McLean’s long-term career? A: A single, resolved episode with no residual deficits is unlikely to have a lasting career effect. More protracted or recurrent vestibular problems would necessitate longer rehabilitation and might affect availability and mechanics, which could influence career trajectory.

Q: How do teams prevent these situations from disrupting tournament plans? A: Teams build depth, maintain clear medical protocols, and employ designated pools and contingency plans. Transparent communication between club and national medical staffs reduces delays and ensures consistent decision-making.

Q: Should fans worry about McLean’s immediate health? A: Current reports indicate symptoms cleared by Tuesday. That is encouraging. Fans should await official updates from the Mets and Team USA medical staff, who will provide functional testing results before clearing him to pitch.

Nolan McLean’s brief absence provides an instructive case on how modern baseball navigates sudden medical issues at the intersection of club responsibility and international ambition. The next few days will clarify whether this rookie's WBC moment arrives as planned or whether Team USA leans on veteran depth. Either way, the priority remains clear: accurate diagnosis, measured recovery and decisions grounded in objective functional testing that protect both player welfare and the team’s competitive interests.